PL2331538T3 - Krystaliczne postacie 2-tiazolylo-4chinolinyl-oksy-pochodnej, silnego inhibitora HCV - Google Patents
Krystaliczne postacie 2-tiazolylo-4chinolinyl-oksy-pochodnej, silnego inhibitora HCVInfo
- Publication number
- PL2331538T3 PL2331538T3 PL09792493T PL09792493T PL2331538T3 PL 2331538 T3 PL2331538 T3 PL 2331538T3 PL 09792493 T PL09792493 T PL 09792493T PL 09792493 T PL09792493 T PL 09792493T PL 2331538 T3 PL2331538 T3 PL 2331538T3
- Authority
- PL
- Poland
- Prior art keywords
- quinolinyl
- thiazolyl
- crystalline forms
- hcv inhibitor
- oxy derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9729108P | 2008-09-16 | 2008-09-16 | |
| US15082609P | 2009-03-09 | 2009-03-09 | |
| EP09792493.0A EP2331538B1 (en) | 2008-09-16 | 2009-09-14 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
| PCT/US2009/056772 WO2010033444A1 (en) | 2008-09-16 | 2009-09-14 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2331538T3 true PL2331538T3 (pl) | 2014-09-30 |
Family
ID=41268627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09792493T PL2331538T3 (pl) | 2008-09-16 | 2009-09-14 | Krystaliczne postacie 2-tiazolylo-4chinolinyl-oksy-pochodnej, silnego inhibitora HCV |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8232293B2 (pl) |
| EP (2) | EP2331538B1 (pl) |
| JP (2) | JP5520301B2 (pl) |
| KR (1) | KR101653550B1 (pl) |
| CN (1) | CN102159571B (pl) |
| AR (1) | AR073298A1 (pl) |
| AU (1) | AU2009293494B2 (pl) |
| BR (1) | BRPI0918513A2 (pl) |
| CA (1) | CA2737055C (pl) |
| CL (1) | CL2011000558A1 (pl) |
| CO (1) | CO6351741A2 (pl) |
| CY (1) | CY1115253T1 (pl) |
| DK (1) | DK2331538T3 (pl) |
| EA (1) | EA018603B1 (pl) |
| EC (1) | ECSP11010878A (pl) |
| ES (1) | ES2474992T3 (pl) |
| HK (1) | HK1156624A1 (pl) |
| HR (1) | HRP20140666T1 (pl) |
| IL (1) | IL210345A (pl) |
| MA (1) | MA32633B1 (pl) |
| ME (1) | ME01831B (pl) |
| MX (1) | MX2011002828A (pl) |
| MY (1) | MY153093A (pl) |
| NZ (2) | NZ591013A (pl) |
| PE (2) | PE20130307A1 (pl) |
| PL (1) | PL2331538T3 (pl) |
| PT (1) | PT2331538E (pl) |
| RS (1) | RS53292B (pl) |
| SG (1) | SG189740A1 (pl) |
| SI (1) | SI2331538T1 (pl) |
| TW (1) | TWI471323B (pl) |
| UY (1) | UY32119A (pl) |
| WO (1) | WO2010033444A1 (pl) |
| ZA (1) | ZA201100096B (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| MX2011002828A (es) | 2008-09-16 | 2011-04-05 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. |
| WO2010033443A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| US9522068B2 (en) * | 2009-03-13 | 2016-12-20 | The University Of Toledo | Minimally invasive collapsible cage |
| WO2010107965A1 (en) * | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
| EP2427434B1 (en) | 2009-05-05 | 2017-05-31 | Boehringer Ingelheim International GmbH | Process for preparing bromo-substituted quinolines |
| PL2451438T3 (pl) | 2009-07-07 | 2014-07-31 | Boehringer Ingelheim Int | Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C |
| CN102596201A (zh) | 2009-10-30 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案 |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| MX2013003060A (es) * | 2010-09-30 | 2013-05-30 | Boehringer Ingelheim Int | Terapia de combinacion para tratar infeccion por hcv. |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| EA201400808A1 (ru) | 2012-01-12 | 2015-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Стабилизированные фармацевтические составы сильнодействующего ингибитора вируса гепатита с |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| CA2903831A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of hcv inhibitor in the amorphous state |
| JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃ型肝炎ウイルスの大環状二環式阻害剤 |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022107182A1 (en) * | 2020-11-18 | 2022-05-27 | University Of Petra | A composition of fentanyl and fatty acids, and a method of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1033128B2 (en) | 1993-09-28 | 2011-11-23 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
| UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
| EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
| MX2011002828A (es) | 2008-09-16 | 2011-04-05 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2009
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en active Application Filing
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko active IP Right Grant
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 RS RS20140230A patent/RS53292B/en unknown
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
-
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
- 2011-10-17 HK HK11111031.5A patent/HK1156624A1/xx not_active IP Right Cessation
-
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
-
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
-
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
- 2014-07-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1156624A1 (en) | Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4-- | |
| PT2155200T (pt) | Forma cristalina de um derivado de carbamoil-ciclohexano | |
| HK1205125A1 (en) | Polymorphic forms of a macrocyclic inhibitor of hcv hcv | |
| IL221123A (en) | Powerful polythrocyclic compounds as hcv inhibitors | |
| HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
| GB0819182D0 (en) | Crystalline forms | |
| EP2176407A4 (en) | METHOD FOR STRUCTURING A SUBSTRATE | |
| EP2162237A4 (en) | METHOD FOR STRUCTURING A SUBSTRATE | |
| IL196706A0 (en) | Crystalline forms of rapamycin analogs | |
| IL221198A0 (en) | Crystalline salts of a potent hcv inhibitor | |
| HK1164698A1 (en) | Crystalline forms of genistein | |
| SI2358676T1 (sl) | Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine | |
| SI2049480T1 (sl) | 2-arilindolni derivati kot mPGES-1 inhibitorji | |
| ZA201100999B (en) | Synthesis of a crystalline silicoaluminophosphate | |
| PL2343292T3 (pl) | Nowa pochodna prostaglandyny I<sub>2</sub> | |
| ZA200903614B (en) | New crystalline forms | |
| ZA201104319B (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
| AP2013006733A0 (en) | Solid state forms of a potent HCV inhibitor | |
| IL210777A0 (en) | Crystalline forms of a pyridine derivative | |
| IL208543A (en) | History of the eupyrpine peptide as potent inhibitors of encephalin-actopeptidase joint | |
| EP1983997A4 (en) | CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE | |
| ZA200900740B (en) | Crystalline forms of rapamycin analogs | |
| HU0800755D0 (en) | Novel crystalline forms | |
| IL213288A0 (en) | Crystalline forms | |
| GB0817164D0 (en) | Crystalline forms |